New data informs decision-making for breast cancer surgeries, highlighting significant findings in outcomes and treatment strategies.
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, two studies presented at the American Society of Breast Surgeons Annual Meeting provide new comparative outcome data to assist with decision‐making for breast cancer surgeries. In addition, the HER2 ‐targeting TKI zongertinib showed a benefit in patients with advanced HER2 ‐mutant non–small cell lung cancer, and in comparison with the 2/20/20 model, use of the AQUILA criteria resulted in a 3‐fold greater number of patients with smoldering multiple myeloma who were classified as high risk.
No takes yet. Share an insight, caveat, or question.
Leah Lawrence (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: